Many of you will know Dr Jonathan Wallis who has been a Consultant Haematologist at the Freeman Hospital, Newcastle-upon-Tyne for many years. He has also been a member of the MPN Voice Steering Committee since MPN Voice was first formed as a charity in 2003. Jonathan has recently retired from both roles and we would…
Professor Ruben Mesa, MD, Dr Robyn Scherber MD, and Dr Angela Fleischman MD, of the Mayo Clinic in Arizona invite you to participate in their survey, the NUTRIENT Trial. This survey is open to MPN patients worldwide. Greetings to our myeloproliferative neoplasm (MPN) patients and dear friends! We would like to tell you a little…
CTI Biopharma have issued the top-line results of the PERSIST-2 study, which you can read here… Professor Claire Harrison says of the results: I am very happy to see these positive results for the effectiveness and safety of pacritinib which will now hopefully quickly become more widely available for patients with low blood counts and myelofibrosis.…
We are happy to share with everyone a very positive outcome from the NICE review of ruxolitinib. Particular thanks to everyone who responded to information requests, our patient attendees, patient advocacy teams and clinical experts. What has NICE said? Ruxolitinib (Jakavi) is recommended as a possible treatment for treating disease-related splenomegaly or symptoms in adults…